Phillips-Medisize
Phillips-Medisize has announced a 6,000 m2 expansion to its Kontiolahti, Finland site, which focuses on the production of complex drug delivery devices such as inhalers, injection pens and safety syringes. The facility manufactures various products from multi-component drug delivery devices in prototype form to finished drug delivery devices in a high-speed, automated production environment.
The expansion was driven by new opportunities that Phillips-Medisize has been awarded over the past 12 months as well as increased global demand for devices with precise dosage drug delivery requirements that the company currently manufactures at the site.
The capacity addition should be online by August of 2013 and will increase moulding and assembly capabilities at the site. Staffing will also be increased by over 15% during the next two years. Today, 336 professionals are focused on meeting the needs of drug delivery device customers around the world.
The combination of a stable and experienced medical work force, extensive in-house tool making, cutting edge metrology, modern cleanrooms and high-volume injection moulding and automated assembly capabilities underlines the company’s mission to provide outstanding support to OEM customers.
Commenting on this plant expansion, Matt Jennings, President and CEO of Phillips
Medisize, said: “This plant expansion is in keeping with our global strategy of offering design and development services and associated manufacturing processes for our medical customers. We support this strategy by investing in our people, processes and facilities to assure we can meet the quality, service and performance expectations of our customers. Although a portion of this new capacity will be taken up by recent wins, we did also plan for future customer growth requirements in this expansion.”
Phillips-Medisize Corp, eu_sales@phillipsmedisize.com, www.phillipsmedisize.com.